ImmunoPET Imaging of Trop2 Expression in Bladder Cancer Using [⁶⁴Cu]Cu-NOTA-Trodelvy

Area of Science:

• Oncology
• Radiochemistry
• Molecular Imaging

Background:

• Trop2 is highly expressed in many solid tumors, including bladder cancer, and drives tumor progression.
• Trop2 expression is minimal in healthy tissues, making it a promising target for cancer imaging and therapy.

Purpose of the Study:

• To evaluate the efficacy of [64Cu]Cu-NOTA-Trodelvy for immunoPET imaging of Trop2 expression in bladder cancer models.
• To assess the specificity and pharmacokinetics of [64Cu]Cu-NOTA-Trodelvy for noninvasive Trop2 visualization.

Main Methods:

• Utilized [64Cu]Cu-NOTA-Trodelvy for immunoPET imaging in HT-1376 bladder cancer models.
• Compared tumor uptake with control groups, including blocking and non-specific IgG conjugates.
• Employed long-term fluorescence imaging with IRDye 800CW-Trodelvy to confirm tumor uptake.

Main Results:

• [64Cu]Cu-NOTA-Trodelvy visualized tumors as early as 12 hours post-injection, with peak uptake at 48 hours (13.73 ± 1.16% ID/g).
• Control groups showed significantly lower tumor uptake, confirming specificity.
• Fluorescence imaging corroborated high and sustained tumor accumulation of Trodelvy.

Conclusions:

• [64Cu]Cu-NOTA-Trodelvy enables specific and prolonged tumor accumulation in bladder cancer models.
• This tracer holds potential for precise, noninvasive monitoring of Trop2 expression in bladder cancer.
• ImmunoPET imaging with [64Cu]Cu-NOTA-Trodelvy can aid in evaluating Trop2-targeted therapies.